Standard BioTools Inc.
NASDAQ:LABMedical - Devices
+$0.03 today
- Market cap
- $225.03M
- Beta
- 1.38
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$0.24
Volume 0.70M
Average 2.91M
LAB Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Standard BioTools Inc.NASDAQ: LAB
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns positive
Q1 FY2026 net income was $127.07M, compared with -$26.03M a year earlier. Trailing-twelve-month net income was $78.21M. Over 3 fiscal years it compounded at -26.7% a year.
Context
- Net income amounted to 87.8% of revenue in FY2025, up 8.1 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$38.16M (-49.0%) for the fiscal year ending Dec 2026, a slowdown from the -46.1% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $127.07M+559.0% QoQ
- Last fiscal yearDec 2025
- -$74.9M-46.1% YoY
- LTMMar 2026
- $78.21M+158.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +588.1% | -85.0% | -673.1 pp |
| 1 year | -46.1% | -49.0% | -3.0 pp |
| 3-year CAGR | -26.7% | -10.6% | +16.0 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (74.9M) USD
- Year-over-year change
- +46.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (74.9M) | +46.1% |
| FY2024 | 2024-12-31 | (138.89M) | -86.0% |
| FY2023 | 2023-12-31 | (74.66M) | +60.7% |
| FY2022 | 2022-12-31 | (190.1M) | -220.9% |
| FY2021 | 2021-12-31 | (59.24M) | — |
Net Income vs competitors
How LAB compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +158.9% is the 3rd highest of 11, against a peer median of +19.4%.
- Net income amounts to 90.7% of revenue for LAB, versus a peer median of 16.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | CN¥246.9M CNY | -58.1% | +55.2% | 16.3% | |
| LTM Mar 2026 | $221.04M USD | +23.7% | — | — | |
| LTM Mar 2026 | $136.99M USD | -8.6% | -3.2% | 173.0% | |
| LTM Apr 2026 | $82.7M USD | +98.8% | — | 9.6% | |
| LTM Mar 2026 | $78.21M USD | +158.9% | -26.7% | 90.7% | |
| LTM Mar 2026 | $74.4M USD | -80.7% | — | 10.4% | |
| LTM Mar 2026 | $74M USD | +557.6% | — | 36.2% | |
| LTM Mar 2026 | $61.04M USD | +15.2% | +11.3% | 29.4% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $60.37M USD | +35.0% | +12.9% | 63.5% |
| LTM Mar 2026 | $39.68M USD | -2.5% | — | 16.3% | |
| LTM Mar 2026 | $33.69M USD | +201.9% | — | 5.8% | |
| Peer median (excluding LAB) | — | +19.4% | +12.1% | 16.3% | |
Competitors are the stored peer set for LAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (59.24M) | (190.1M) | (74.66M) | (138.89M) | (74.9M) |
| Depreciation & Amortization | 16.2M | 15.03M | 15.18M | 16.86M | 1.72M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 16.1M | 14.88M | 13.12M | 31.73M | 29.61M |
| Change in Working Capital | (18.01M) | (12.35M) | 1.79M | (12.08M) | (44.98M) |
| Accounts Receivables | 6.73M | 1.06M | (2.99M) | 8.97M | (1.36M) |
| Inventory | (4.78M) | (8.47M) | (4.91M) | (9.88M) | (11.52M) |
| Accounts Payables | 0 | 0 | 1.62M | 0 | 2.44M |
| Other Working Capital | (19.95M) | (4.95M) | 8.07M | (11.17M) | (34.53M) |
| Other Non-Cash Items | 886K | 83.17M | 1.28M | (41.08M) | 14.2M |
| Operating Cash Flow | (44.06M) | (89.37M) | (43.29M) | (143.45M) | (74.35M) |
| Capital Expenditures | (13.26M) | (3.83M) | (2.83M) | (8.36M) | (8.3M) |
| Acquisitions (Net) | 0 | 0 | 0 | 278.65M | 0 |
| Purchases of Investments | 0 | 0 | (94.9M) | 0 | (140.93M) |
| Sales of Investments | 0 | 0 | 117.96M | 0 | 179M |
| Other Investing Activities | 1.32M | (84.3M) | 0 | 92.88M | (5M) |
| Investing Cash Flow | (11.95M) | (88.13M) | 20.24M | 363.17M | 24.77M |
| Debt Repayment | 9.5M | 18.16M | (2.08M) | (63.19M) | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 1.05M |
| Common Stock Repurchased | (1.79M) | (774K) | (5.41M) | (40.95M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 8.25M | 213.37M | 827K | 1.53M | (484K) |
| Financing Cash Flow | 15.96M | 230.76M | (6.81M) | (102.62M) | 570K |
| Effect of Forex Changes | (21K) | (404K) | 34K | (785K) | 842K |
| Net Change in Cash | (40.07M) | 52.86M | (29.83M) | 116.32M | (48.17M) |
| Free Cash Flow | (57.33M) | (93.2M) | (46.12M) | (151.81M) | (82.65M) |
Standard BioTools Inc.
NASDAQ:LAB
Intrinsic Alpha fair value
Locked
Current Price
$0.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.